Lead Product(s) : Abciximab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients
Details : Abciximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 22, 2017
Lead Product(s) : Abciximab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abciximab
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
Details : Abciximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Sickle Cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 30, 2013
Lead Product(s) : Abciximab
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
